-

Agilent Presents Thought Leader Award to IIT Delhi Scientist Professor Anurag Rathore

Prof. Rathore is the first researcher in India to receive this award; he has been recognized for his contributions to biopharmaceutical research

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) has honored Prof. Anurag Rathore, a scientist at the Indian Institute of Technology (IIT) Delhi, with an Agilent Thought Leader Award, for his contributions to the field of biopharmaceutical research and his work with advanced methods for molecular characterization of biosimilars.

The 2020 award includes a grant to support research personnel and Agilent instrumentation including a 6545XT AdvanceBio LC/Q-TOF, a Bravo Automated Liquid Handling Platform, and a 1290 Infinity II 2D-LC System. Prof. Rathore—who serves as a professor at IIT Delhi’s Chemical Engineering department—is the first researcher in India to receive this award. Award funding will be used to promote academic-based research on critical areas impacting the biopharmaceutical industry.

“I feel humbled to be chosen for an Agilent Thought Leader Award,” said Prof. Rathore. “As one of the many researchers at IIT Delhi working in the new COVID-19 normal, this is an encouraging and welcome event. The award will propel me to work harder as we strive to bring the technologies and products we have been working on to market.”

The work at Prof. Rathore’s lab will focus on the best practices towards molecular characterization of monoclonal antibody-based biosimilars. Monoclonal antibodies (mAbs) include an important and growing group of biopharmaceutical drugs used to treat several diseases and conditions. Their activity, stability, and other physicochemical and toxicological characteristics are heavily influenced by the level and position of their amino acid modifications. As such, Agilent is invested in developing workflows to streamline the analysis of critical charge and glycosylation heterogeneity of these molecules.

“Prof. Rathore is a leading scientist among an extremely motivated and talented research group at IIT Delhi. We are privileged to have him as the first recipient of an Agilent Thought Leader Award in India,” said Bharat Bhardwaj, country general manager for Agilent India. “This award will bring financial support, cutting-edge products, consumables, services, and, most importantly, Agilent expertise to his research.”

Bhardwaj continued, “Over the next three years, this relationship will further help Prof. Rathore’s development of biosimilar drugs, and improving human health.”

The Agilent Thought Leader Award program promotes fundamental scientific advances by contributing financial support, products, and expertise to the research of influential thought leaders in the life sciences, diagnostics, and chemical analysis space. Further information is available on the Agilent Thought Leader Award web page.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics, and applied chemical markets, delivering insight and innovation toward improving the quality of life. Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.34 billion in fiscal 2020 and employs 16,400 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter, and Facebook.

Contacts

Monica Dhawan
Agilent Technologies, India
+91 124 268 5417
monica.dhawan@agilent.com

Naomi Goumillout
Agilent Technologies, USA
+1.781.266.2819
naomi.goumillout@agilent.com

Agilent Technologies Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Versions

Contacts

Monica Dhawan
Agilent Technologies, India
+91 124 268 5417
monica.dhawan@agilent.com

Naomi Goumillout
Agilent Technologies, USA
+1.781.266.2819
naomi.goumillout@agilent.com

More News From Agilent Technologies Inc.

Agilent Reports First-Quarter Fiscal Year 2026 Financial Results

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies, Inc. (NYSE: A) today reported revenue of $1.80 billion for the first quarter ended Jan. 31, 2026, representing growth of 7.0% reported and up 4.4% core(1) compared with the first quarter of 2025. First-quarter GAAP net income was $305 million, or $1.07 per share. This compares with $318 million, or $1.11 per share, in the first quarter of 2025. Non-GAAP(2) net income was $386 million, or $1.36 per share, during the quarter, compared wi...

Agilent to Participate in TD Cowen’s 46th Annual Health Care Conference

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that Chief Financial Officer Adam Elinoff and Head of Investor Relations Tejas Savant will participate in a fireside chat at TD Cowen’s 46th Annual Health Care Conference. The event is scheduled for 11:10 to 11:40 a.m. EST on Tuesday, March 3, 2026, in Boston, Massachusetts. A live audio webcast and replay of the presentation will be available through Agilent’s Investor Relations website. About Agilent Tec...

Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved PD-L1 IHC 22C3 pharmDx, Code SK006, as the only FDA-approved companion diagnostic indicated to aid in identifying patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC), whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. PD-L1 IHC 22C3 pharm...
Back to Newsroom